Premium
A new immunohistochemistry‐based assay SBrC5 classifies invasive breast cancer subtypes ‐profiling five biomarkers in one single test
Author(s) -
Haiping Liu,
Muralitharan Sharmini
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.834.1
Subject(s) - breast cancer , immunohistochemistry , cytokeratin , subtyping , biomarker , concordance , tissue microarray , medicine , skbr3 , cancer , staining , pathology , oncology , cancer research , biology , human breast , biochemistry , computer science , programming language
Obtaining expression status of ER, PR and Her2 is essential for guiding treatment and predicting outcome for breast cancers. It has been reported that by adding cytokeratin 5/6 and EGFR to the above biomarkers, a five‐biomarker breast cancer panel had been validated for identifying the basal‐like subtype with superior prognostic values than the triple negative subtype1. The current study aims to evaluate a new immunohistochemical assay, named Subtyping Breast Cancers 5‐in‐1 Assay (SBrC5) for classifying breast cancer subtypes. A cocktail of ER, PR, Her2, cytokeratin 5/ 6 and EGFR antibodies (SBrC5 Cocktail) and the MultiVision Detection Kit (two colors, red and blue) were used. The assay was performed on a breast cancer tissue microarray of 75 cases. Both color and cellular localization of the staining was used for the result interpretation. There were three staining clusters: 1) Red Nuclei indicated ER or PR positive; 2) Red Membrane indicated Her2 expression; and 3) Blue Membrane or Cytoplasm indicated EGFR or cytokeratine 5/6 positivity respectively. The concordance for the assay when compared to the individual tests for each biomarker were 94.1%, 93.8% and 92.4% for Her2, combined ER and PR, and combined cytokeratine 5/6 and EGFR respectively. It is concluded that the SBrC5 assay is able to provide sufficient information for classifying breast cancer subtypes with only a single IHC test.